Copyright timesnownews
Teva Pharmaceuticals USA Inc. has voluntarily recalled more than half a million bottles of its blood pressure medication after tests revealed high levels of a potentially cancer-causing chemical, following a report from the US Food and Drug Administration (FDA), reports NBC Chicago. The New Jersey-based drugmaker pulled 580,844 bottles of Prazosin Hydrochloride capsules from the market nationwide, the FDA’s enforcement report showed. The recall, initiated on Oct. 7, affects 1 mg, 2 mg and 5 mg doses of the medication. The capsules were found to contain “above acceptable intake limits” of N-nitroso Prazosin impurity C, a compound linked to cancer, according to the FDA report. On Oct. 24, the recall was classified as Class II, meaning the product may cause temporary or medically reversible adverse health effects, while the risk of serious health consequences remains low. Teva’s health hazard assessment rated the potential harm to patients as “medium,” the California Board of Pharmacy said in a memo. Only specific lots of the drug were affected, and the FDA has published a list of the recalled batches. Prazosin, sold under the brand name Minipress, is an alpha-blocker commonly prescribed to treat high blood pressure, according to the Cleveland Clinic. The recall comes a month after another major drug recall involving Lipitor, a widely used cholesterol medication, which was pulled for “failed dissolution specifications,” meaning the pills might not dissolve properly and could reduce the drug’s effectiveness. Patients using Prazosin are advised to check the FDA’s list of affected lot numbers and consult their healthcare providers before stopping or changing their medication. Get Latest News Live on Times Now along with Breaking News and Top Headlines from US News and around the World.
